Moxifloxacin Anfarm

Moxifloxacin, the active ingredient in Moxifloxacin Anfarm, is a fluoroquinolone presented as an intravenous formulation for parenteral use. It is employed to treat a range of serious bacterial infections, particularly in adult patients with community‑acquired pneumonia, sinusitis, bronchitis exacerbations, skin‑structure infections, and complicated intra‑abdominal infections.

GNH USA supplies Moxifloxacin Anfarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Moxifloxacin is indicated for several bacterial infections affecting the respiratory and other systems.

- Community‑acquired bacterial pneumonia: provides bacterial eradication and clinical improvement. - Acute bacterial sinusitis: reduces infection signs and promotes sinus drainage. - Acute bacterial exacerbation of chronic bronchitis: helps resolve bacterial flare‑ups. - Skin and skin structure infections: achieves bacterial clearance in soft‑tissue infections. - Complicated intra‑abdominal infections: assists in controlling polymicrobial abdominal infections.

Moxifloxacin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, often self‑limiting. - Headache: transient cranial discomfort. - Rash: mild skin erythema. - Elevated liver enzymes: transient laboratory changes. - Transient visual disturbances: blurred vision or photophobia.

Serious or Rare Side Effects: - Tendon rupture: especially Achilles tendon, requiring immediate medical attention. - QT interval prolongation: may predispose to cardiac arrhythmias. - Severe hypersensitivity reactions: including Stevens‑Johnson syndrome. - Clostridioides difficile colitis: severe diarrhea due to bacterial overgrowth. - Hepatotoxicity: significant liver injury. - Peripheral neuropathy: persistent sensory changes.

Moxifloxacin should be used with caution in specific clinical situations.

- Tendon safety: avoid use in patients with a history of tendon disorders or concurrent corticosteroid therapy. - Cardiac risk: monitor patients with known QT prolongation or electrolyte abnormalities. - Renal impairment: adjust therapy in severe renal dysfunction. - Hepatic function: use cautiously in patients with liver disease. - Pregnancy and lactation: avoid unless the benefit outweighs potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Moxifloxacin may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Antacids containing magnesium or aluminum: reduce absorption of moxifloxacin. - Warfarin: may increase anticoagulant effect, requiring INR monitoring. - Cyclosporine: increased risk of nephrotoxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of CNS stimulation. - Theophylline: potential for increased serum levels and toxicity. - Corticosteroids: heightened risk of tendon rupture.